MedMira
MedMira receives CE mark for its VYRA™ COVID-19 Antigen Test
Halifax, Nova Scotia, 14 October, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™...
top of page
MedMira
- Oct 3, 2022
- 4 min
MedMira provides Progress Update
Halifax, Nova Scotia, 30 September, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as...
MedMira
- Sep 27, 2022
- 1 min
Latest announcement by the FDA
We are delighted for the move forward by the FDA. While the EUA is still an on-going process, the FDA is ready for highly anticipated...
MedMira
- Sep 21, 2022
- 2 min
MedMira announces the appointment of Dr. Sam Ratnam as Director of Scientific & Regulatory Affairs
The management and board is delighted to have Dr. Ratnam joining our growing team and support MedMira’s various regulatory applications....
MedMira
- Sep 20, 2022
- 1 min
MedMira Receives US Trademark for its REVEALCOVID-19
MedMira is delighted to announce the receipt of the United States of America Trademark for its REVEALCOVID-19 brand. The Company has been...
MedMira
- Sep 14, 2022
- 1 min
Notification of upcoming updates
MedMira will be providing an update with the latest milestones achieved and additional news over the coming weeks. At this stage we would...
bottom of page